The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | First analysis of VenDd +/- V for RRMM shows unprecedented reponse
Nizar Bahlis
• 10 Dec 2019
Nizar Bahlis, MD, University of Calgary, Calgary, AB, Canada, discusses the first analysis from M15-654 (NCT03314181), a phase I/II, non-randomized, multicenter study of venetoclax in combination with daratumumab and dexamethasone (VenDd), with or without bortezomib (V), in patients with relapsed/refractory multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
